The latest episode of a regional news outlet on German television network SAT.1 featured Prof.Klusmann and Prof.Heckl. The interview gives insights on possible applications of micro RNAs in cancer therapies.

Leukemia explained: In the latest episode of the KGU Gesundheitsforum Prof. Jan-Henning Klusmann gives a straightforward explanation to the origins of leukemia and our treatment advances, featuring Stephanie as special guest.

An exiting delivery has arrived at the lab. A new server cabinet and additonal equipment was setup by our bioinformatics team. The new set up will provide extended data storage and increased computational capacities.

A local newspaper has recently featured a portartit article about our groupleader Prof. Klusmann and his tasks and goals as director of the pediatric hospital in Frankfurt.

Oriol Alejo-Valle's work was published as a Plenary Paper in BLOOD. We describe the molecular basis for the dual differentiation block in Down syndrome megakaryoblastic leukemia.

From the clinical side of our lab: Sina presents recommendations for the diagnosis and treatment of children with transient abnormal myelopoiesis and Down syndrome myeloid leukemia.

Congratulations to Dr. rer. nat. Oriol Alejo-Valle on a successful PhD dissertation! His is the first defense from our group that has been held in Halle, and concludes our "batch from 2015".

Another partial lab move is coming up! As of July 1st, Prof. Klusmann has joined the Universitätsklinikum Frankfurt as Head of Pediatrics. Students and postdocs will follow in October.

In our latest review article, we provide a comprehensive overview of the molecular basis of step-wise leukemogenesis in Down syndrome-associated myeloid leukemia and transient abnormal myelopoiesis.

We congratulate Dr. rer. nat. Michelle Ng on an excellent virtual PhD defense. Following this, she graduated from the HBRS Molecular Medicine PhD program with highest honours.

Many congratulations to Dr. rer. nat. Dorit Schneider, who overcame pandemic-related challenges and successfully defended her PhD! She completed the Molecular Medicine program with a magna cum laude.

This review summarizes recent research on RBPs with roles in acute leukemias, focusing on the proteins' functional domains, the pathways they affect, and clinical aspects associated with their dysregulation.

Prof. Klusmann was awarded this year's Johann Georg Zimmermann Prize, which recognizes outstanding young investigators for their contribution to the fight against cancer.

Our latest publication reports on the characterization of HOXA10-AS, a novel stem cell-specific lncRNA that is required for the maintenance of MLL-rearranged acute myeloid leukemias.

Our congratulations to Maurice, who won this year's Cord-Michael Becker Prize for his outstanding PhD work in the field of Molecular Medicine. This is a highly prestigious national award!

At this year's ISEH meeting in Brisbane, Australia, Dorit won both a travel award as well as a Young Investigator Prize for her short talk on EZH2 loss and co-operating mutations. We are so proud!

Our congratulations to Dirk Heckl, who has now officially joined the faculty of the Universitätsklinikum Halle as professor of Experimental Pediatrics, after more than a year apart.

Two of our papers went online this week! 1) Identification and validation of molecular events that drive progression from transient abnormal myelopoiesis to full-blown Down syndrome myeloid leukemia.

Two of our papers went online this week! 2) A review article on the regulatory roles of long noncoding RNAs in acute myeloid leukemia, including an updated catalog of functionally defined examples.

Another excellent PhD defense this year! Congratulations to Dr. rer. nat. Sofia Gialesaki, who graduated with a summa cum laude in June - among the first from the PhD program's entering class of 2015!

We are very proud of Sofia, who won a YoungEHA Best Abstract Award and presented the RUNX1 story to thousands during the EHA 2019 Presidential Symposium today. Yay Sofia!

Following an excellent thesis defense, Dr. rer. nat. Maurice Labuhn graduated with a summa cum laude from the HBRS Molecular Medicine PhD program. Many congratulations!

The TMD Prevention 2007 trial found that low-dose cytarabine treatment reduced mortality in TMD patients. However, this therapy did not prevent disease progression to ML-DS.

We have an open position for a skilled and dedicated postdoc in our new laboratory in Halle. Applications are welcome until the end of February. See the full post for more details.

The proceeds from this year's Charity Day were given to Pediatrics I of the Universitätsklinikum Halle. The funds will support research on leukemia in children with Down sydrome.

CRISPR-Cas9 genome editing was used to induce GATA1s in HSPCs of fetal, neonatal, and adult origin, leading to distinct ontogeny-specific disturbances in megakaryopoiesis and erythropoiesis.

The tumor suppressor miR-193b is downregulated in AML. Expression induces leukemic cell death through repression of MAPK signalling, making miR-193b a candidate for RNA-based therapy.

Introducing CRISPRater: a tool for more efficiently selecting effective sgRNAs in CRISPR-Cas9 applications. In addition, we provide a meta-analysis and individual evaluation of five current prediction algorithms.

Jan-Henning Klusmann will become full professor and department head of Pediatric Hematology/Oncology at the Universitätsklinikum Halle! He will begin there in January, and students will follow in March.

PD Dr. Jan-Henning Klusmann is a co-winner of the this year's Robert J. Arceci Award, a unique prize that offers resources and freedom to pioneers and innovators in childhood cancer research.

Our latest publication provides a non-coding RNA expression atlas across normal and malignant blood cells. We highlight the biological and clinical importance of ncRNAs, and the need for further study.

Two publications in one day: 1) Leveraging CRISPR-Cas9 to model translocation-driven leukemia yields new insight into the importance of environmental cues during disease induction.

Two publications in one day: 2) Targeted gene correction in induced pluripotent stem cells from Kostmann disease patients reverted the disease phenotype and rescued granulocytic function.

We are looking for a proactive and creative team player capable of designing and carrying out experiments independently. Experience with cell culture and molecular biology preferred.

Results from the international ML-DS 2006 trial indicate that children with Down syndrome acute myeloid leukemia can be cured with a less intensive, less cytotoxic treatment regime.

All five of our PhD students showed posters at the ISALXVI in Munich. Dorit was further selected as a Best of Free Contributions and gave a talk and interview about her research.

Congratulations to Dr. rer. nat. Erik Pittermann, who has graduated from the Regenerative Sciences PhD program (HBRS/REBIRTH Cluster of Excellence) with a magna cum laude grade.

PD Dr. Jan-Henning Klusmann's "iAML-lncTARGET" project has received 1.5 million Euros in funding from the European Research Council's (ERC) prestigious ERC Starting Grant.

In collaboration with a multi-national group, we have succeeded in targeting cancer cells by blocking autophagy. This may represent a new therapeutic option for treating acute leukemias.

The Evangelische Johannesstift has donated 364,000 Euros to fund research on early childhood leukemias. PD Dr. Jan-Henning Klusmann of Pediatric Hematology and Oncology was the recipient.

Congratulations to Dr. Razan Jammal, who graduated today from the HBRS Molecular Medicine PhD program. She successfully defended her thesis and received a magna cum laude.

Eight of our students presented their work this year at the 29th Annual Kind Philipp Meeting in Wilsede. Michelle received the first Kind Philipp Presentation Award for unpublished research.

At this year's Johannes Brodehl Symposium, Erik Pittermann was awarded the first "Zellkraftwerk Nachwuchsforscherpreis" (Prize for Young Scientists) for his promising PhD work.

Dr. Jan-Henning Klusmann has received the 10,000 Euro Kind-Philipp Prize, in appreciation of his research work on childhood blood cancers at the Hannover Medical School.

Dr. Klusmann's research group reveals the interplay between three microRNAs in the development of acute megakaryoblastic leukemia. Their findings were published in Genes & Development.